Xofluza(Baloxavir marboxil)

This prescription drug was approved by the FDA in the United States in 2018. It targets the cap-dependent endonuclease of influenza A and B viruses and must be used strictly under medical supervision.

Target of Action

Cap-dependent endonuclease of influenza A and B viruses

Dosage and Administration

Route and frequency of administration for Baloxavir marboxil (Xofluza): Oral, once daily.

The dosage of Baloxavir marboxil (Xofluza) should be adjusted based on the patient's actual condition. For specific details, consult your doctor and follow medical advice.

Recommended reading: Dosage and Administration of Baloxavir marboxil (Xofluza)

Side Effects

Common side effects: Diarrhea, bronchitis, nausea, etc.

Serious side effects: Difficulty breathing, rash, urticaria or blisters, etc.

Reference article: Side Effects of Baloxavir marboxil (Xofluza)

Use in Special Populations

Pregnancy: It is currently unknown whether Baloxavir marboxil (Xofluza) can harm your unborn baby.

Breastfeeding: It is currently unknown whether Baloxavir marboxil (Xofluza) passes into your breast milk.

Daily Precautions

1. Baloxavir marboxil (Xofluza) may contain inactive ingredients that could cause allergic reactions or other problems.

2. Follow all instructions on the drug label and package. Inform every healthcare provider of all your health conditions, allergies, and all medications you are using.

FDA，2025.05